Applying Population Management Best Practices to Preventative Genomic Medicine Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

900 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-01

Study Completion Date

2028-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preventive genomic medicine, particularly identification of individuals with inherited cancer risk, can improve longevity and quality of life, yet adherence to risk management following cancer genomic testing is poor. The proposed research refines and evaluates two highly scalable population management interventions, web resources and personalized outreach, designed to improve access and use of recommended risk management following cancer genetic testing. Research activities will be conducted in a vertically integrated health system and federally qualified health center and will address post-testing quality and patient safety concerns that are minimizing patient benefit and slowing investments in real world genomic medicine implementation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Implementing Personal Health Records to Promote Evidence-Based Cancer Screening

NCT02138448

Cancer Health Promotion

COMPLETED NA

Increasing Implementation of Evidence-based Interventions at Low-wage Worksites

NCT02005497

Cancer Health Promotion

COMPLETED NA

Communicating Multiple Disease Risks: A Translation of Risk Prediction Science

NCT03255291

Healthy Volunteers

COMPLETED NA

Broadening the Reach, Impact, and Delivery of Genetic Services

NCT03985852

Cancer Risk Reduction Behavior

COMPLETED NA

Project CARE: CAncer Risk Evaluation

NCT07130487

Primary Care

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preventive genomic medicine, particularly identification of individuals with inherited cancer risk, provides health systems with the opportunity to improve longevity and quality of life for their patients. The ability to uncover substantially elevated risk of disease through genomic testing, act to reduce that risk, and improve outcomes while lowering costs has been the longstanding promise of genomic medicine. In the case of inherited cancer, however, adherence to recommended risk management following genomic testing is low. Further, our pilot data suggests that health systems are reluctant to expand cancer genomic testing without a clearer idea of how to manage tested patients over time. Our goal in this application is to address this roadblock to genomic medicine implementation. Specifically, we will demonstrate the benefits that adopting population management interventions following genomic testing can provide health systems, using hereditary cancer as a case example. We will revise and rigorously evaluate two population management interventions (web resources and personalized outreach) that improve timely patient outreach and end-to-end tracking without burdening providers. Web resources is a low-touch intervention that links patients with existing educational resources. Personalized outreach is a high-touch intervention that connects patients with a dedicated care manager to discuss risk management and provide care reminders.

Both interventions are highly scalable and mirror population management programs that health systems have used to support cancer screening, diabetes management, and other evidence-based care for decades. We will compare web resources and personalized outreach to usual care in a pragmatic hybrid type-1 randomized trial that engages patients captured in hereditary cancer registries within two health systems, Kaiser Permanente Northwest (KPNW) and Denver Health (DH). KPNW is a vertically integrated health system and DH is a federally qualified health center, providing two highly unique evaluation settings. Our primary effectiveness outcome is adherence to recommended cancer screening over one year. We will collect secondary implementation outcomes, including the acceptability, appropriateness, feasibility, sustainability, and costs of high- and low-touch intervention approaches. By providing clinical champions with essential data and tools to select and implement population management interventions that address critical gaps in post-testing quality and patient safety, this innovative project will advance preventive genomic medicine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplastic Syndromes, Hereditary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual care

No intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Web resources

Individuals randomized to web resources will be sent materials refined in Aim 1 (via patient portal and USPS mail) within 1-2 weeks after their birthday. Messages will be sent in English or preferred language noted in the EHR.

Group Type EXPERIMENTAL

Web resources

Intervention Type BEHAVIORAL

Mailed educational resources through portal and USPS mail

Personalized outreach

Individuals randomized to personalized outreach will be contacted by the care coordinator in their birthday month for a brief phone call discussing due and overdue screening. The coordinator will attempt to contact patients up to 3 times to complete the phone conversation before considering them opting out of the intervention. If needed, the coordinator can place orders and pending referrals for PCP signature.

Group Type EXPERIMENTAL

Personalized outreach

Intervention Type BEHAVIORAL

Phone call to discuss due and overdue screening and other personalized risk management recommendations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Web resources

Mailed educational resources through portal and USPS mail

Intervention Type BEHAVIORAL

Personalized outreach

Phone call to discuss due and overdue screening and other personalized risk management recommendations

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically actionable variant in at least one high penetrance cancer-related gene
* Age- and sex- eligible for guideline indicated risk management
* Remains eligible for risk management, given personal cancer and surgical history

Exclusion Criteria

* Previously opted out of research
* Previously opted out of genetic research
* On hospice or palliative care
* Has advanced dementia or severe cognitive impairment

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No